Please assess the completion status of the following clinical trial:

Trial Title: PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Severe heart failure (NYHA grade III or IV)~* Chronic kidney disease stage 3-4~* Fluid overload resistant to diuretics OR hospital admission for HF in last 6 months~* Left ventricular ejection fraction ≤40% in last 2 years (moderate/severe)~* Using optimal HF medication for ≥ 4 weeks including ACE-inhibitor (angiotensin-converting-enzyme inhibitor) OR angiotensin receptor blocker AND aldosterone antagonist AND beta-blocker unless intolerant and without dose change for ≥ 4 weeks~* Appropriately screened for revascularization and/or cardiac resynchronization therapy if clinically indicated.~Exclusion Criteria:~* Does not wish to participate~* Mental incapacity to consent~* CKD stage 5~* Normal renal excretory function~* Haemodynamically significant valvular disease amenable to surgery~* Cardiac or renal transplantation~* Considered by the investigator to unsuitable for PD due to previous abdominal surgeries, peritonitis, social circumstances or other reason

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peritoneal Dialysis Group (Type: EXPERIMENTAL): These participants will continue to receive standard HF care and Peritoneal Dialysis with a single daily exchange of icodextrin.
- Control Group (Type: NO_INTERVENTION): These participants will continue to receive standard HF care.

Based on this trial design, predict the completion outcome and termination type (if applicable).